

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HUA MEDICINE

華領醫藥

(Incorporated in the Cayman Islands with limited liability)

(stock code: 2552)

GRANT OF SHARE OPTIONS

This announcement is made pursuant to Rule 17.06A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

The board (the “**Board**”) of directors (the “**Directors**”) of Hua Medicine (the “**Company**”) announces that on August 21, 2026, the Company granted share options (the “**Share Options**”) to one employee of the Company (the “**Grantee**”) pursuant to the Company’s share option scheme which was conditionally approved and adopted on August 26, 2018 and effective beginning September 14, 2018 (the “**Share Option Scheme**”), subject to acceptance by the Grantee. The Share Options entitle the Grantee to subscribe for a total of 200,000 new shares with a nominal value of US\$0.001 each (the “**Shares**”) in the share capital of the Company.

Details of the Share Options granted are as follows:

Date of the grant: August 21, 2026

Exercise price of the Share Options granted: HK\$2.6 per Share, which is the highest of:

- i. the closing price of HK\$2.6 per Share as stated in the daily quotation sheets issued by The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) on the date of grant of the Share Options;
- ii. the average closing price of HK\$2.519 per Share as stated in the daily quotation sheets issued by the Stock Exchange for the five (5) business days immediately preceding the date of grant of the Share Options; and
- iii. the nominal value of US\$0.001 per Share.

Number of Share Options granted: 200,000 Share Options. Each Share Option shall entitle the holder thereof to subscribe for one (1) Share.

Validity period and vesting period of the Share Options:	Ten (10) years from the date of grant. 25% of the Share Options shall be vested on the first anniversary of the date of grant. The remaining 75% of the Share Options shall be vested in 36 monthly installments thereafter, subject to the Grantee's continued employment from the date of grant.
Performance targets and clawback mechanisms:	There is no performance target or clawback mechanism attached to the Share Options granted. The Grantee is a senior manager of the Company. Taking into consideration that the grant is to attract and retain high quality talent for a key position of the Company, which is critical for the Company's future development and growth, the Remuneration Committee of the Company is of the view that it is not necessary to set any performance target or clawback mechanism for the grant because such grant could reinforce the Grantee's commitment to long term services of the Company. As such, the arrangement is aligned with the purpose of the Share Option Scheme.

Save as disclosed above, to the best knowledge, information and belief of the Directors, having made all reasonable enquiries, the Grantee is not (i) a Director, chief executive or substantial shareholder of the Company or their associate (as defined in the Listing Rules); (ii) a participant with options and awards granted and to be granted exceeding the 1% individual limit under Rule 17.03D of the Listing Rules; or (iii) a related entity participant or service provider with options and awards granted and to be granted in any 12-month period exceeding 0.1% of the total issued Shares.

Subsequent to the grant of the Share Options, the number of Shares available for future grant under the scheme mandate pursuant to the Share Option Scheme is 16,707,902.

The Share Option Scheme was adopted before the effective date of the new Chapter 17 of the Listing Rules. The Company will comply with the new Chapter 17 to the extent required by the transitional arrangements for the existing share schemes.

By Order of the Board

Dr. Li Chen

Chief Executive Officer and Executive Director

Hong Kong, August 21, 2026

As of the date of this announcement, the Board comprises Dr. Li Chen, Mr. George Chien Cheng Lin and Dr. Yi Zhang as executive Directors; Mr. Robert Taylor Nelsen as non-executive Director; and Mr. William Robert Keller, Mr. Yiu Wa Alec Tsui and Mr. Yiu Leung Andy Cheung as independent non-executive Directors.